We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Events

08 Dec 2026 - 10 Dec 2026
25 Jan 2027 - 28 Jan 2027

Digital Twins Predict Treatment Response in Triple-Negative Breast Cancer

By HospiMedica International staff writers
Posted on 01 Nov 2026

Triple-negative breast cancer (TNBC) is an aggressive, fast-growing subtype that accounts for about 15% of all breast cancer cases. More...

Its tumor cells lack estrogen receptors, progesterone receptors, and the HER2 protein, limiting the use of hormone therapies and HER2-targeted drugs. With these treatment limitations in mind, researchers have developed a computer model based on symbolic artificial intelligence to help identify additional options when standard therapies fail.

Developed by a University College London team in collaboration with the University of Cambridge, the model uses an individual patient’s detailed genetic fingerprint to recommend potential treatment options for TNBC. It relies on symbolic AI, which uses logical reasoning and allows clinicians to see how recommendations are generated, providing transparency that “black box” artificial intelligence models lack.

To evaluate the approach, the researchers created computer-generated tumors, or digital twins, based on tumors from 31 patients in the PARTNER clinical trial. The trial’s full name is Platinum and PolyAdenosine 5'-Diphosphoribose Polymerisation Inhibitor for Research and Treatment of Neo-Adjuvant Early and Relapse-Risk Breast Cancer. Using these digital twins, the team simulated three scenarios: chemotherapy alone, chemotherapy combined with olaparib, and no treatment.

The researchers then compared the simulations with clinical trial outcomes and found that the model correctly predicted whether treatment would work in 74% of cases. Among 13 patients who did not respond fully, the digital twins identified at least one additional targeted treatment for 12 patients that might have improved outcomes. For 10 of these patients, the model predicted that adding the treatment could produce a sufficient response that no invasive cancer would likely remain in the breast or lymph nodes afterward.

The inclusion of olaparib reflects a biological vulnerability found in some TNBC tumors. Homologous recombination deficiency affects roughly 15% to 20% or more of cases and can make tumors vulnerable to drugs that block poly-ADP ribose polymerase, or PARP, an enzyme involved in repairing single-strand DNA breaks. Olaparib is a PARP inhibitor and was used in the PARTNER trial, led by the University of Cambridge and Addenbrooke’s Hospital, Cambridge, between 2016 and 2024. The findings were published in Cell Reports Medicine on October 26, 2026.

Related Links
University College London 


Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Immobilization System
Cranial 4Pi Immobilization
Monitor/Defibrillator
Zenix
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image Credit: Shutterstock

Explainable AI Examines Sepsis Mortality Risk and Emergency Care Delays

Preventing sepsis-related deaths in emergency departments (EDs) remains challenging because patient deterioration can result from multiple rapidly evolving and interconnected factors. These include triage... Read more

Patient Care

view channel
Image: A view inside the custom virtual reality environment used in the study: a calm room with a teddy bear, soft colors and large windows looking out over the sea. (Image Credit: Walaa S. Abu Rukbah et al., Virginia Commonwealth University; CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Virtual Reality Program May Reduce Anxiety Before Pediatric Surgery

Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more

Medical Imaging

view channel
Image: A new automated approach could help predict which patients with dystonia will benefit from deep brain stimulation before surgery (Image Credit: Adobe Stock)

AI Uses Routine MRI to Predict Deep Brain Stimulation Response in Dystonia

Dystonia is a debilitating neurological movement disorder characterized by involuntary muscle contractions that cause abnormal movements and postures. Deep brain stimulation (DBS) is one of the few treatments... Read more

Health IT

view channel
Image Credit: Shutterstock

Telemonitoring Program Improves Quality of Life After Heart Failure Discharge

Heart failure is a chronic condition associated with high mortality, frequent hospitalizations, and reduced quality of life. Patients face particularly high risks of readmission and death after discharge,... Read more

Point of Care

view channel
Image: Jessica Ramella-Roman, professor of biomedical engineering at Florida International University, holding the PPRIM (Portable Preterm Imaging) device designed to detect early signs of preterm labor risk. (Photo courtesy of Florida International University)

Handheld Imaging Device May Help Identify Preterm Birth Risk Earlier

Preterm birth, defined as delivery before 37 weeks of pregnancy, can lead to serious neonatal complications, including neurological, developmental, and respiratory problems. However, identifying pregnancies... Read more

Business

view channel
Image: Stryker has acquired ZuriMED, adding the FiberLocker System, a rotator cuff augmentation technology designed to strengthen repairs, to its Sports Medicine portfolio. (Photo courtesy of ZuriMED)

Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings

Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.